Warning letter
Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine: warning letter of Nov 10, 2021
FDA warning letter 615908 · Division of Pharmaceutical Quality Operations Division III
Key facts
| Reference number | 615908 |
|---|---|
| Company | Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Nov 10, 2021 |
| Posted date | Nov 16, 2021 |
| Issuing office | Division of Pharmaceutical Quality Operations Division III |
| Product type | Drugs |
| CFR sections cited | 201.115, 211.87, 200.10(b), 211.28(a), 211.42(a), 211.42(c)(10)(iv), 211.94(c), 211.100(a), 211.113(b), 210.1(b), 211.188(b) |
| Inspection city | Indianapolis |
| Inspection ZIP | 46240-1806 |
| Inspection start date | Oct 13, 2020 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: